PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.

Published on Sep 8, 2020in Blood Advances4.584
· DOI :10.1182/BLOODADVANCES.2020001584
Neus Serrat2
Estimated H-index: 2
,
Martina Guerrero-Hernández2
Estimated H-index: 2
+ 18 AuthorsPatricia Pérez-Galán16
Estimated H-index: 16
Sources
Abstract
Despite idelalisib approval in relapsed follicular lymphoma (FL), a complete characterization of the immunomodulatory consequences of phosphatidylinositol 3-kinase δ (PI3Kδ) inhibition, biomarkers of response, and potential combinatorial therapies in FL remain to be established. Using ex vivo cocultures of FL patient biopsies and follicular dendritic cells (FDCs) to mimic the germinal center (n = 42), we uncovered that PI3Kδ inhibition interferes with FDC-induced genes related to angiogenesis, extracellular matrix formation, and transendothelial migration in a subset of FL samples, defining an 18-gene signature fingerprint of idelalisib sensitivity. A common hallmark of idelalisib found in all FL cases was its interference with the CD40/CD40L pathway and induced proliferation, together with the downregulation of proteins crucial for B-T-cell synapses, leading to an inefficient cross talk between FL cells and the supportive T-follicular helper cells (TFH). Moreover, idelalisib downmodulates the chemokine CCL22, hampering the recruitment of TFH and immunosupressive T-regulatory cells to the FL niche, leading to a less supportive and tolerogenic immune microenvironment. Finally, using BH3 profiling, we uncovered that FL-FDC and FL-macrophage cocultures augment tumor addiction to BCL-XL and MCL-1 or BFL-1, respectively, limiting the cytotoxic activity of the BCL-2 inhibitor venetoclax. Idelalisib restored FL dependence on BCL-2 and venetoclax activity. In summary, idelalisib exhibits a patient-dependent activity toward angiogenesis and lymphoma dissemination. In all FL cases, idelalisib exerts a general reshaping of the FL immune microenvironment and restores dependence on BCL-2, predisposing FL to cell death, providing a mechanistic rationale for investigating the combination of PI3Kδ inhibitors and venetoclax in clinical trials.
References56
Newest
#1Annika Scheffold (University of Ulm)H-Index: 11
#2Billy Michael Chelliah Jebaraj (University of Ulm)H-Index: 9
Last. Stephan Stilgenbauer (University of Ulm)H-Index: 113
view all 20 authors...
Targeted therapy is revolutionizing the treatment of cancers, but resistance evolves against these therapies and derogates their success. The phosphatidylinositol 3-kinase delta (PI3K-δ) inhibitor idelalisib has been approved for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, but the mechanisms conferring resistance in a subset of patients are unknown. Here, we modeled resistance to PI3K-δ inhibitor in vivo using a serial tumor transfer and treatment scheme in mice. Wh...
17 CitationsSource
#1Nitin Jain (University of Texas MD Anderson Cancer Center)H-Index: 43
#2Michael J. Keating (University of Texas MD Anderson Cancer Center)H-Index: 163
Last. William G. Wierda (University of Texas MD Anderson Cancer Center)H-Index: 114
view all 32 authors...
Abstract Background Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia...
185 CitationsSource
#1Stalin Chellappa (Oslo University Hospital)H-Index: 4
#2Kushi KushekharH-Index: 9
Last. Kjetil Taskén (Oslo University Hospital)H-Index: 73
view all 7 authors...
In chronic lymphocytic leukemia (CLL), signaling through several prosurvival B cell surface receptors activates the PI3K signaling pathway. Idelalisib is a highly selective PI3K (PI3Kδ) isoform-specific inhibitor effective in relapsed/refractory CLL and follicular lymphoma. However, severe autoimmune adverse effects in association with the use of idelalisib in the treatment of CLL, particularly as a first-line therapy, gave indications that idelalisib may preferentially target the suppressive fu...
66 CitationsSource
#1Kamil Bojarczuk (Harvard University)H-Index: 11
#2Kirsty Wienand (Harvard University)H-Index: 7
Last. Margaret A. Shipp (Harvard University)H-Index: 93
view all 11 authors...
Inhibition of the B-cell receptor (BCR) signaling pathway is a promising treatment strategy in multiple B-cell malignancies. However, the role of BCR blockade in diffuse large B-cell lymphoma (DLBCL) remains undefined. We recently characterized primary DLBCL subsets with distinct genetic bases for perturbed BCR/phosphoinositide 3-kinase (PI3K) signaling and dysregulated B-cell lymphoma 2 (BCL-2) expression. Herein, we explore the activity of PI3K inhibitors and BCL-2 blockade in a panel of funct...
41 CitationsSource
#1Shuai DongH-Index: 6
Last. John C. ByrdH-Index: 137
view all 12 authors...
: Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110δ inhibitor idelalisib. Here, we found that genetic inactivation of p110δ (p110δD910A/D910A) in the Eμ-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and significantly delayed leukemia pathogenesis. Regardless of TCL1 expression, p110δ inactivation led to recta...
23 CitationsSource
BCL-2 family proteins regulate the intrinsic pathway of programmed cell death (apoptosis) and play a key role in the development and health of multicellular organisms. The dynamics of these proteins’ expression and interactions determine the survival of all cells in an organism, whether the healthy cells of a fully competent immune system or the diseased cells of an individual with cancer. Anti-apoptotic proteins like BCL-2, BCL-XL and MCL-1 are well known for maintaining tumor cell survival and...
15 CitationsSource
#1Ralf Küppers (University of Duisburg-Essen)H-Index: 88
#2Freda K. Stevenson (Southampton General Hospital)H-Index: 80
The development of follicular lymphoma (FL) from a founder B cell with an upregulation of B-cell lymphoma 2 (BCL2), via the t(14;18) translocation, to a proliferating clone, poised to undergo further transformation to an aggressive lymphoma, illustrates the opportunistic Darwinian process of tumorigenesis. Protection against apoptosis allows an innocent cell to persist and divide, with dangerous accumulation of further mutational changes, commonly involving inactivation of chromatin-modifying ge...
24 CitationsSource
#1Sarah Huet (French Institute of Health and Medical Research)H-Index: 12
#2Pierre Sujobert (French Institute of Health and Medical Research)H-Index: 17
Last. Gilles Salles (French Institute of Health and Medical Research)H-Index: 111
view all 3 authors...
This Review discusses the mutational landscape and evolution of follicular lymphoma. Deciphering the earliest initiating lesions and the molecular alterations leading to disease progression might help identify the most relevant targets for therapy of these tumours.
61 CitationsSource
#1Jordi Ochando (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 32
#2Mounia S. Braza (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 6
// Jordi Ochando 1 and Mounia S. Braza 1 1 Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Correspondence to: Mounia S. Braza, email: mounia.braza@mssm.edu Keywords: immunotherapy; helper T cells; TFH cells; B cell non-Hodgkin lymphoma; follicular lymphoma Received: July 14, 2017 Accepted: November 20, 2017 Published: November 30, 2017 ABSTRACT Follicular lymphoma (FL), the most common indolent B-cell non-Hodgkin lymphoma...
11 CitationsSource
#1Tracy Lackraj (Princess Margaret Cancer Centre)H-Index: 2
#2Rashmi S. Goswami (Princess Margaret Cancer Centre)H-Index: 14
Last. Robert Kridel (Princess Margaret Cancer Centre)H-Index: 28
view all 3 authors...
Abstract Follicular lymphoma (FL) is presented as a germinal centre B cell lymphoma that is characterized by an indolent clinical course, but remains – paradoxically – largely incurable to date. The last years have seen significant progress in our understanding of FL lymphomagenesis, which is a multi-step process beginning in the bone marrow with the hallmark t(14;18)(q32;q21) translocation. The pathobiology of FL is complex and combines broad somatic changes at the level of both the genome and ...
24 CitationsSource
Cited By8
Newest
#1Bart Vanhaesebroeck (UCL: University College London)H-Index: 85
#2Perry Matthew (AstraZeneca)H-Index: 18
Last. Klaus Okkenhaug (University of Cambridge)H-Index: 64
view all 5 authors...
Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has been hampered by issues such as poor drug tolerance and drug resistance, several PI3K inhibitors have now received regulatory approval — the PI3Kα isoform-selective inhibitor alpelisib for the treatment of breast cancer and inhibitors mainly aimed at the leukocyte-enriched PI3Kδ in B cell malignancies. In addition to targeting ...
3 CitationsSource
Follicular lymphoma (FL) is a paradigm of tumors that require the interaction between tumor and microenvironment cells to foster their development from initial steps to progression. Recent large-scale genome studies have uncovered multiple genetic alterations of FL that influence the microenvironment in two main directions, promoting tumor cell survival and proliferation and facilitating their evasion from immune antitumor signals. Understanding the crosstalk between tumor B-cells and the microe...
Source
In the follicular lymphoma (FL) microenvironment, CXCR5+ICOS+PD1+BCL6+ follicular helper T (Tfh) cells, which closely correlate with FL B cells in neoplastic follicles, play a major role in supporting FL. Interleukin-4 secreted by Tfh cells triggers the upregulation of the lymphocyte chemoattractant CXCL12 in stromal cell precursors, in particular by fibroblastic reticular cells (FRCs). In turn, mesenchymal fistromal cells (MSCs) can be committed to FRC differentiation in the bone marrow and lym...
Source
#1Juan G. ValeroH-Index: 8
#2Alba Matas-Céspedes (AstraZeneca)H-Index: 7
Last. Patricia Pérez-GalánH-Index: 16
view all 20 authors...
Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favo...
2 CitationsSource
#1Giulia Petroni (Cornell University)H-Index: 6
#2Aitziber Buqué (Cornell University)H-Index: 23
Last. Lorenzo GalluzziH-Index: 127
view all 5 authors...
At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer a...
19 CitationsSource
Since the opening of the economy, China’s regional economy has developed rapidly, the overall national strength has been increasing, and the people’s living standards have been continuously improved. The issue of coordinated regional development has become an important issue in today’s society. Genetic algorithm is a kind of prediction algorithm that has developed rapidly in recent years and is widely used. However, when solving engineering prediction problems, there are often problems such as p...
Source
Last. Patricia Pérez-GalánH-Index: 16
view all 5 authors...
Follicular Lymphoma (FL), the most common indolent non-Hodgkin’s B cell lymphoma, is a paradigm of the immune microenvironment’s contribution to disease onset, progression, and heterogeneity. Over the last few years, state-of-the-art technologies, including whole-exome sequencing, single-cell RNA sequencing, and mass cytometry, have precisely dissected the specific cellular phenotypes present in the FL microenvironment network and their role in the disease. In this already complex picture, the p...
2 CitationsSource
#1Lutz Menzel (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 2
#2Uta E. Höpken (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 30
Last. Armin Rehm (MDC: Max Delbrück Center for Molecular Medicine)H-Index: 19
view all 3 authors...
Tumor-induced remodeling of the microenvironment in lymph nodes (LNs) includes the formation of blood vessels, which goes beyond the regulation of metabolism, and shaping a survival niche for tumor cells. In contrast to solid tumors, which primarily rely on neo-angiogenesis, hematopoietic malignancies usually grow within pre-vascularized autochthonous niches in secondary lymphatic organs or the bone marrow. The mechanisms of vascular remodeling in expanding LNs during infection-induced responses...
1 CitationsSource